Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H29N5O3 |
| Molecular Weight | 387.476 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCNC(=O)NC1CCN(CC1)C2=C3C=C(OC)C(OC)=CC3=NC=N2
InChI
InChIKey=CPZHDDGPHQRMEJ-UHFFFAOYSA-N
InChI=1S/C20H29N5O3/c1-4-5-8-21-20(26)24-14-6-9-25(10-7-14)19-15-11-17(27-2)18(28-3)12-16(15)22-13-23-19/h11-14H,4-10H2,1-3H3,(H2,21,24,26)
Buquineran (UK14275), an inotropic compound, is a coronary vasolidator agent. It has been shown to exert a
powerful inotropic effect with minimal effect on heart rate in dogs. Buquineran is a phosphodiesterase inhibitor. It acted as potent inhibitor of cyclic AMP hydrolysis catalysed by both PDE-II and PDE-III enzymes.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0004115 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2825712 |
7.6 µM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/498597
Electrophysiological and haemodynamic measurements were made in six dogs over
successive 30 min periods under control conditions and during infusion of Buquineran at 50,
100 and 250 ug/kg per min (infusion rates 0.91, 1.82 and 4.55 ml/min), respectively.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2825712
Buquineran inhibited PDE-II and PDE-III activity with IC50 value of 7.6 uM and 8.6 uM, respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C012675
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
SUB05986MIG
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
DTXSID30207924
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
AWC1VMS3HC
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
C74355
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
59184-78-0
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
100000088450
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL26984
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
4477
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY | |||
|
71953
Created by
admin on Mon Mar 31 18:33:03 GMT 2025 , Edited by admin on Mon Mar 31 18:33:03 GMT 2025
|
PRIMARY |
ACTIVE MOIETY